Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Melbourne (Australia) – 3 May 2021. Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Register Interest

Telix is pleased to announce several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Dr. David Cade, who has served as Telix’s Chief Business Officer and Head of Investor Relations since joining Telix in 2019, has been appointed President of Telix APAC. In this role, David will lead Telix’s commercial activities across the Asia-Pacific region, including Telix’s anticipated approval of Illuccix^® in Australia and other regional territories. Mr. Jonathan Barlow, previously Telix’s General Counsel will take an expanded executive role of Chief Business Development Officer and Group General Counsel and will be responsible for leading Telix’s business development and legal functions globally. Telix has additionally recruited a Senior Vice President of Investor Relations and Corporate Communications, with a planned commencement date of early July.

Dr. Tracey Brown, who joined Telix in February 2020, has been appointed Global Senior Vice President of Product Portfolio Management. Dr. Brown will be responsible for driving the development of Telix’s broad pipeline from early development through to commercialization. Dr. Michael Wheatcroft, who has served as Telix’s Director of R&D since the inception of the company, has been promoted to the executive role of Chief Scientist. Dr. Wheatcroft will be responsible for Telix’s research and innovation (R&I) programs globally, reflective of Telix’s strong portfolio development in key areas such as Targeted Alpha Therapy.

As announced today, Mr. Richard Valeix has joined Telix as President Europe, Middle East and Africa (EMEA), succeeding Mr. Ludovic Wouters who has served as Interim President of Telix EMEA for the past 15 months. Mr. Wouters will remain a key executive member of the European business development team.

Telix Chief Executive Officer Dr. Christian Behrenbruch stated, “These appointments reflect a significant restructuring of the business that is designed to support the transition to a commercial stage company. I would like to particularly recognise David Cade’s outstanding contribution to the business and my support of his transition to the APAC leadership role. I’d also like to personally thank Ludo Wouters for his excellent leadership through a period of significant growth in the European team and the pivotal role Ludo has played in the recruitment of Richard to the EU team.”

To read the full ASX disclosure please click here.

About Telix Pharamceuticals (ASX: TLX)

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix’s products address significant unmet medical needs in prostate, kidney, glioblastoma (brain) and hematologic (blood) cancers, as well as a range of immunologic and high value rare diseases.

The Company is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States, and is listed on the Australian Securities Exchange (ASX: TLX).

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix’s products have currently received a marketing authorisation in any jurisdiction. For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Register Interest